Please login to the form below

Not currently logged in
Email:
Password:

Elocta

This page shows the latest Elocta news and features for those working in and with pharma, biotech and healthcare.

Shire claims EU approval for haemophilia A drug Adynovi

Shire claims EU approval for haemophilia A drug Adynovi

Shire claims EU approval for haemophilia A drug Adynovi. The drug will battle Bayer’s Kovaltry and Sobi's Elocta in a bid to capture market share. ... It is jostling for market share with other long-acting Factor VIII products for haemophilia A,

Latest news

More from news
Approximately 3 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • A rare opportunity A rare opportunity

    The process is never guaranteed, but we are hoping Elocta will be accessible to patients from 1 July,” he says. ... Compared to normal timelines, the requirements for haemophilia could be quite frustrating, but Neil is sanguine about the need to wait,

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics